Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2026-03-11 @ 2:10 AM
Study NCT ID:
NCT00541333
Status:
SUSPENDED
Last Update Posted:
2013-05-03
First Post:
2007-10-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
Sponsor:
The New York Eye & Ear Infirmary
Organization:
Study Overview
Official Title:
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
Status:
SUSPENDED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Reviewing data
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: